Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Results of Operations and Financial Condition

Axovant Sciences Ltd. (NYSE:AXON) Files An 8-K Results of Operations and Financial Condition

Story continues below

Item 2.02 Results of Operations and Financial Condition.

On June 13, 2017, Axovant Sciences Ltd. (the Registrant) issued a
press release announcing its financial results for the three
months and year ended March 31, 2017. A copy of this press
release is furnished herewith as Exhibit 99.1 to this Current
Report on Form 8-K and is incorporated herein by reference.
In accordance with General Instruction B.2. of Form 8-K, the
information in this Item 2.02 and Exhibit 99.1 hereto, shall not
be deemed filed for purposes of Section 18 of the Securities
Exchange Act of 1934, as amended (the Exchange Act), or otherwise
subject to the liability of that section, nor shall it be deemed
incorporated by reference in any of the Registrants filings under
the Securities Act of 1933, as amended, or the Exchange Act,
whether made before or after the date hereof, regardless of any
incorporation language in such a filing, except as expressly set
forth by specific reference in such a filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
Description
99.1
Press Release of Axovant Sciences Ltd., dated June 13,
2017, Axovant Sciences Announces Fiscal Year-End
Financial Results and Corporate Updates


About Axovant Sciences Ltd. (NYSE:AXON)

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., is a clinical-stage biopharmaceutical company focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Company focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders. The Company’s focus is to develop its lead product candidate, Intepirdine, which is a selective 5-hydroxytryptamine 6 (5-HT6) receptor antagonist for the treatment of Alzheimer’s disease and dementia with Lewy bodies (DLB). The Company also focuses on developing its second product candidate, Nelotanserin, which is a selective 5-HT2A receptor inverse agonist for the treatment of visual hallucinations in patients with DLB and rapid eye movement (REM) behavior disorder (RBD) in patients with DLB.

An ad to help with our costs